SuperworthRepligen EPS RGEN
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $0.73
- Latest quarter, Q2 FY26
- $0.09
- −65% on a year earlier
- Fiscal year 2025
- $0.85
Repligen's earnings per share was $0.73 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was $0.09, down 65% on the same quarter a year before.
Over the five fiscal years to FY2025 it shrank 5% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $0.85 | n/a |
| FY2024 | −$0.45 | −171% |
| FY2023 | $0.63 | −81% |
| FY2022 | $3.25 | +45% |
| FY2021 | $2.24 | +102% |
| FY2020 | $1.11 | +152% |
| FY2019 | $0.44 | +22% |
| FY2018 | $0.36 | −49% |
| FY2017 | $0.71 | +109% |
| FY2016 | $0.34 | +17% |
| FY2015 | $0.29 | +16% |
| FY2014 | $0.25 | −49% |
| FY2013 | $0.49 | +9% |
| FY2012 | $0.45 | n/a |
| FY2011 | −$0.11 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.09 | −65% | $0.73 | |
| Q1 FY26 | $0.15 | +50% | $0.90 | |
| Q4 FY25 | $0.23 | n/a | $0.85 | |
| Q3 FY25 | $0.26 | n/a | $0.02 | |
| Q2 FY25 | $0.26 | +160% | −$0.25 | |
| Q1 FY25 | $0.10 | +67% | −$0.41 | |
| Q4 FY24 | −$0.60 | n/a | −$0.45 | |
| Q3 FY24 | −$0.01 | −103% | −$0.14 | |
| Q2 FY24 | $0.10 | −71% | $0.17 | |
| Q1 FY24 | $0.06 | −78% | $0.42 | |
| Q4 FY23 | −$0.29 | −134% | $0.63 | |
| Q3 FY23 | $0.30 | −58% | $1.77 |
Against its peers
Companies in Biotechnology nearest Repligen's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| RGENRepligen | $0.73 | |
| KRYSKrystal Biotech | $7.98 | +62% a year |
| TECHBIO-TECHNE | $1.15 | +150% a year |
| HALOHalozyme Therapeutics | $3.35 | −23% a year |
| NBIXNeurocrine Biosciences | $6.82 | +102% a year |
| EXELExelixis | $3.18 | +53% a year |
| INCYIncyte | $7.85 | +78% a year |
| UTHRUnited Therapeutics | $27.95 | +9% a year |
| ALNYAlnylam Pharmaceuticals | $5.93 | |
| ADMAAdma Biologics | $0.70 | −18% a year |
| ONCBeOne Medicines | $0.43 | |
| Peer median | $4.64 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Repligen
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.